TY - JOUR
T1 - Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia
T2 - Results of a randomized, controlled study
AU - Schiller, Gary
AU - Nimer, Stephen
AU - Gajewski, James
AU - Lee, Myung
AU - Ho, Winston
AU - Territo, Mary
AU - Champlin, Richard
PY - 1993
Y1 - 1993
N2 - The optimal dose and schedule of cytarabine in induction chemotherapy of newly diagnosed acute myelogenous leukemia is not established. We compared the use of cytarabine 200 mg/ m*day by continuous infusion for seven days to an intermediate-dose of cytarabine, 500 mg/m- every 12 hours for 12 doses. Thirty-seven of 52 patients assigned to conventional-dose cytarabine achieved complete remission (71% and the actuarial disease-free and overall survival after achieving remission were 22 ± 16% and 31 t 19% respectively. Thirty-seven of 50 patients assigned to intermediate-dose cytarabine achieved remission (74% and the actuarial disease-free and overall survival after achieving remission were 26 ± 16% and 39 ± 18% respectively. There were no statistically significant differences in complete remission rate, actuarial leukemia-free survival or overall survival between the groups. The most significant predictor for survival was age. Actuarial two year leukemia-free survival and overall survival for patients age >60 were 8 ± 15% and 20 ± 19% respectively compared to 36 2 14% and 54 ± 15% for patients age ≤60 (P =.058 and. 01, respectively). Induction regimen did not significantly affect disease free or overall survival for patients under or over age 60. We conclude that intermediate-dose cytarabine did not substantially improve results of induction for newly diagnosed acute myeloid leukemia.
AB - The optimal dose and schedule of cytarabine in induction chemotherapy of newly diagnosed acute myelogenous leukemia is not established. We compared the use of cytarabine 200 mg/ m*day by continuous infusion for seven days to an intermediate-dose of cytarabine, 500 mg/m- every 12 hours for 12 doses. Thirty-seven of 52 patients assigned to conventional-dose cytarabine achieved complete remission (71% and the actuarial disease-free and overall survival after achieving remission were 22 ± 16% and 31 t 19% respectively. Thirty-seven of 50 patients assigned to intermediate-dose cytarabine achieved remission (74% and the actuarial disease-free and overall survival after achieving remission were 26 ± 16% and 39 ± 18% respectively. There were no statistically significant differences in complete remission rate, actuarial leukemia-free survival or overall survival between the groups. The most significant predictor for survival was age. Actuarial two year leukemia-free survival and overall survival for patients age >60 were 8 ± 15% and 20 ± 19% respectively compared to 36 2 14% and 54 ± 15% for patients age ≤60 (P =.058 and. 01, respectively). Induction regimen did not significantly affect disease free or overall survival for patients under or over age 60. We conclude that intermediate-dose cytarabine did not substantially improve results of induction for newly diagnosed acute myeloid leukemia.
KW - AML randomized controlled study
KW - Cytarabine dose intensity
KW - Long term survival acute leukemia
UR - http://www.scopus.com/inward/record.url?scp=0027438039&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027438039&partnerID=8YFLogxK
U2 - 10.3109/10428199309054732
DO - 10.3109/10428199309054732
M3 - Article
C2 - 8220156
AN - SCOPUS:0027438039
SN - 1042-8194
VL - 11
SP - 69
EP - 77
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1-2
ER -